Soligenix, Inc. (SNGX) shares surged 260.00 percent to $4.50 after announcing that its Phase 2a proof-of-concept study for SGX945 in Behçet's Disease achieved its primary goal of demonstrating biological efficacy.
The stock opened at $1.9010 and traded between $1.6600 and $3.3599, with volume spiking to 174 million shares, vastly exceeding the average of 919,691 on the Nasdaq. Shares had previously closed at $1.2500. The stock now trades near the upper end of its 52-week range of $1.0900 to $5.4000.
The treatment showed comparable results to apremilast in reducing oral ulcers, despite SGX945 being discontinued at week 4, while apremilast continued through week 8—suggesting sustained therapeutic benefit even post-treatment.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.